Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABLAGO Study
2024-518452-23-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Nov 2024
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methimazole and iodine-131 in Graves' disease and Graves' ophthalmopathy (TED) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Response rate at 24 weeks after inclusion. Planned start Nov 2024; status: authorised.
02
Drugs
methimazoleiodine-131
03
Conditions
Graves' diseaseGraves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2024-518452-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518452-23-00.